mhurhangee/patent-ind-claim-en huggingface dataset:
An active vibration reduction control apparatus for a hybrid electric vehicle, the active vibration reduction control apparatus comprising: a reference signal generator generating a reference signal (Wx) and a first phase (θm1) based on a first rotational angle (θm1) of a first motor which is coupled to one side of an engine ; a vibration extractor extracting a vibration signal (Wd) from a second motor which is coupled to another side of the engine ; a coefficient determiner determining a filter coefficient which minimizes a phase difference between the reference signal (Wx) and the vibration signal (Wd); a phase determiner detecting a second phase (θm2) which corresponds to the phase difference between the reference signal (Wx) and the vibration signal (Wd) using a first speed signal (W1m) of the first motor and the filter coefficient; a phase deviation amount detector detecting a third phase (θp) for compensating for a phase delay generated by the vibration extractor using the first speed signal (W1m) of the first motor ; and a synchronization signal generator generating an antiphase signal of a shape of an actual vibration signal (Wd), for a phase determined using the first phase (θm1), the second phase (θm2), and the third phase (θp) using a look-up table for signal amplitude for each of said phases , in order to determine a compensating force of the first motor . a reference signal generator generating a reference signal (Wx) and a first phase (θm1) based on a first rotational angle (θm1) of a first motor which is coupled to one side of an engine ; a vibration extractor extracting a vibration signal (Wd) from a second motor which is coupled to another side of the engine ; a coefficient determiner determining a filter coefficient which minimizes a phase difference between the reference signal (Wx) and the vibration signal (Wd); a phase determiner detecting a second phase (θm2) which corresponds to the phase difference between the reference signal (Wx) and the vibration signal (Wd) using a first speed signal (W1m) of the first motor and the filter coefficient; a phase deviation amount detector detecting a third phase (θp) for compensating for a phase delay generated by the vibration extractor using the first speed signal (W1m) of the first motor ; and a synchronization signal generator generating an antiphase signal of a shape of an actual vibration signal (Wd), for a phase determined using the first phase (θm1), the second phase (θm2), and the third phase (θp) using a look-up table for signal amplitude for each of said phases , in order to determine a compensating force of the first motor .
A three-dimensional scaffold structure comprising scaffold structure parts made of a polymer system and fluid-filled open spaces between the scaffold structure parts with a minimum extent of 50 nm in each spatial direction, the polymer system being obtainable by treating a starting material with electromagnetic radiation, the starting material containing precursor molecules of the formula (I) or inorganic polymers thereof: wherein the radicals and indices have the following meaning: B is a straight-chain or branched or cyclic organic radical having at least one C=C double bond and 4 to 100 carbon atoms; X is hydrogen, halogen, hydroxy, alkoxy, acyloxy, alkylcarbonyl, alkoxycarbonyl or NR 4 2 ; R is alkyl, alkenyl, aryl, alkylaryl or arylalkyl; R 2 is OH, COOH, NR 4 2 , NR 4 2 H + or SH or a derivative thereof, wherein the derivatization results in OR 5 , COOR 5 , NR 4 R 5 , NR 4 R 5 H + or SR 5 , wherein R 5 is the residue of a biofunctional molecule or dye; R 4 is hydrogen, alkyl, aryl or alkylaryl; R Rg is the backbone of a straight-chain or branched hydrocarbon bonded to the Si atom, where the backbone may be interrupted by heteroatoms or heteroatom-containing groups; a = 1, 2 or 3; b = 0, 1 or 2; a+b = 3; c = 1, 2, 3 or 4. B is a straight-chain or branched or cyclic organic radical having at least one C=C double bond and 4 to 100 carbon atoms; X is hydrogen, halogen, hydroxy, alkoxy, acyloxy, alkylcarbonyl, alkoxycarbonyl or NR 4 2 ; R is alkyl, alkenyl, aryl, alkylaryl or arylalkyl; R 2 is OH, COOH, NR 4 2 , NR 4 2 H + or SH or a derivative thereof, wherein the derivatization results in OR 5 , COOR 5 , NR 4 R 5 , NR 4 R 5 H + or SR 5 , wherein R 5 is the residue of a biofunctional molecule or dye; R 4 is hydrogen, alkyl, aryl or alkylaryl; R Rg is the backbone of a straight-chain or branched hydrocarbon bonded to the Si atom, where the backbone may be interrupted by heteroatoms or heteroatom-containing groups; a = 1, 2 or 3; b = 0, 1 or 2; a+b = 3; c = 1, 2, 3 or 4.
Laminated packaging material for liquid food products , comprising a barrier film , a first outermost liquid tight, heat sealable polyolefin layer and a second innermost liquid tight, heat sealable polyolefin layer , the barrier film comprising a polymer film substrate and coated onto a first side of the polymer film substrate, by plasma-enhanced chemical vapour deposition (PECVD) in a vacuum process, a first coating layer of silicon oxide having the general composition formula SiOxCy, wherein x is from 1.5 to 2.2, and y is from 0.15 to 0.8, and a second coating layer of an amorphous diamond-like carbon (DLC), which is directly adjacent and contacting the first coating layer, wherein the total thickness of the first and second coating layers is from 7 to 10 nm, the barrier film providing gas and water vapour barrier properties and mechanical durability in the laminated packaging material and packages made thereof.
Assembly for a brake system of a vehicle, comprising at least one brake control module which has an electronically controlled pressure supply device which, in the installed state of the assembly , is fluidically coupled to at least one wheel brake of the vehicle, and wherein the brake control module is connected to a holding device for arrangement on a vehicle body , characterized in that the brake control module has a mechanical stop device which, in the installed state of the assembly , is spaced apart at a distance from an adjacent vehicle component and, by interaction with the vehicle component, outputs a warning signal in the event of a loss of support of the brake control module .
A method for screening personalized anticancer agents, the method comprising the steps of: (a) selecting candidate anticancer agents based on clinical and genetic information of a patient with cancer; (b) treating cancer cells from a patient with candidate anticancer agents in vitro, measuring the anticancer activity of the treated candidate anticancer agents, and selecting a group of personalized anticancer agent candidates having anticancer activity in vitro, from the candidate anticancer agents; and (c) treating a immunodeficient rodent model containing cancer cells from the patient with the selected candidate group of personalized anticancer agent candidates of step (b) to verify the anticancer effect of the candidate group in vivo, wherein steps (a) and (b) are performed with an avatar scanner apparatus, wherein the avatar scanner apparatus comprises a first means for selecting suitable candidate anticancer agents from the genetic information of the cancer, a second means for collecting cancer cells from a cancer tissue of the patient, and a third means for treating the cancer cells with the selected candidate anticancer agents and analyzing the effect of the candidate anticancer agents, wherein the avatar scanner apparatus includes a culture system, candidate anticancer agent reservoir, a candidate anticancer agent dispenser, a cell survival rate-measuring device, a data storage unit and a data analysis unit, wherein the culture system includes a medium reservoir, a cell dispenser, a medium exchanger, an incubator, a stirrer and a waste discharge unit. (a) selecting candidate anticancer agents based on clinical and genetic information of a patient with cancer; (b) treating cancer cells from a patient with candidate anticancer agents in vitro, measuring the anticancer activity of the treated candidate anticancer agents, and selecting a group of personalized anticancer agent candidates having anticancer activity in vitro, from the candidate anticancer agents; and (c) treating a immunodeficient rodent model containing cancer cells from the patient with the selected candidate group of personalized anticancer agent candidates of step (b) to verify the anticancer effect of the candidate group in vivo, wherein steps (a) and (b) are performed with an avatar scanner apparatus, wherein the avatar scanner apparatus comprises a first means for selecting suitable candidate anticancer agents from the genetic information of the cancer, a second means for collecting cancer cells from a cancer tissue of the patient, and a third means for treating the cancer cells with the selected candidate anticancer agents and analyzing the effect of the candidate anticancer agents, wherein the avatar scanner apparatus includes a culture system, candidate anticancer agent reservoir, a candidate anticancer agent dispenser, a cell survival rate-measuring device, a data storage unit and a data analysis unit, wherein the culture system includes a medium reservoir, a cell dispenser, a medium exchanger, an incubator, a stirrer and a waste discharge unit.
A method for examining a risk of developing an ischemic heart disease or a probability of development of an ischemic heart disease, the method comprising the steps of: measuring a concentration of cyclophilin A protein and a concentration of C-reactive protein in a human blood sample derived from a subject to be examined; and determining, based on the measured concentration of cyclophilin A protein and the measured concentration of C-reactive protein, a probability of development of an ischemic heart disease in the subject to be examined, wherein the determination step comprises determining that the subject to be examined has a risk of developing the ischemic heart disease or has a probability of development of the ischemic heart disease when the sample is evaluated as negative in the high-sensitivity CRP test and the concentration of cyclophilin A protein in the sample is higher than the concentration of cyclophilin A protein in a sample derived from a healthy subject. measuring a concentration of cyclophilin A protein and a concentration of C-reactive protein in a human blood sample derived from a subject to be examined; and determining, based on the measured concentration of cyclophilin A protein and the measured concentration of C-reactive protein, a probability of development of an ischemic heart disease in the subject to be examined, wherein the determination step comprises determining that the subject to be examined has a risk of developing the ischemic heart disease or has a probability of development of the ischemic heart disease when the sample is evaluated as negative in the high-sensitivity CRP test and the concentration of cyclophilin A protein in the sample is higher than the concentration of cyclophilin A protein in a sample derived from a healthy subject.
A multilayer adhesive film comprising: A. as surface adhesive layers, Adhesion Layer 1 ("AL1") and Adhesion Layer 2 ("AL2") wherein Adhesion Layer 1 comprises an adhesive polar ethylene copolymer and wherein Adhesion Layer 2 comprises an adhesive polar ethylene copolymer, wherein said adhesive polar ethylene copolymers are selected from the group consisting of ethylene/α,β-ethylenically unsaturated carboxylic acid copolymers; ethylene vinyl acetate copolymers; ethylene alkyl (meth)acrylate copolymers; and blends of two or more thereof; B. an internal Controlled Bond Layer ("CBL") located between the AL1 and the AL2 and strippably adhered to the AL1 and comprising a propylene-based polymer; C. an internal Strong Bond Layer ("SBL") different than the CBL and located between the CBL and AL2 and having a facial surface in adhering contact to the CBL and wherein the Strong Bond Layer comprises a thermoplastic ethylene-based polymer having a density less than 0.92 g/cm 3 ; and D. optionally, one or more different internal Filler Layer(s) located between the SBL and the adhesive surface layer on the side of the SBL opposite to the adhered CBL; the adhesive film: (i) having a bond strength between the CBL and a non-CBL layer adjacent thereto that is less than the heat activated adhesive bond strengths of the surface layers to surfaces of metal or thermoplastic ethylene polymer and other bond strengths between other adjacent layers in the film, (ii) comprising at least three weight percent recycled film composition in either the SBL or a Filler Layer and, (iii) when adhering a thermoplastic ethylene polymer surface to a metal surface, providing a strippable interface at the CBL; wherein said bond strengths are according to the Adhesion Test Method described in the description. A. as surface adhesive layers, Adhesion Layer 1 ("AL1") and Adhesion Layer 2 ("AL2") wherein Adhesion Layer 1 comprises an adhesive polar ethylene copolymer and wherein Adhesion Layer 2 comprises an adhesive polar ethylene copolymer, wherein said adhesive polar ethylene copolymers are selected from the group consisting of ethylene/α,β-ethylenically unsaturated carboxylic acid copolymers; ethylene vinyl acetate copolymers; ethylene alkyl (meth)acrylate copolymers; and blends of two or more thereof; B. an internal Controlled Bond Layer ("CBL") located between the AL1 and the AL2 and strippably adhered to the AL1 and comprising a propylene-based polymer; C. an internal Strong Bond Layer ("SBL") different than the CBL and located between the CBL and AL2 and having a facial surface in adhering contact to the CBL and wherein the Strong Bond Layer comprises a thermoplastic ethylene-based polymer having a density less than 0.92 g/cm 3 ; and D. optionally, one or more different internal Filler Layer(s) located between the SBL and the adhesive surface layer on the side of the SBL opposite to the adhered CBL;
A distillation process comprising: feeding a feed mixture comprising a hydrochlorofluoroolefin comprising a contaminant to a first distillation column; and extracting the contaminant from the feed mixture in the first distillation column using an extractive solvent comprising a chlorinated compound selected from the group consisting of trichloroethylene, carbon tetrachloride, chloroform, 1,1,1-trichloroethane, and mixtures thereof to form an overhead stream comprising a purified hydrochlorofluoroolefin and a bottoms stream comprising the contaminant and the extractive solvent; wherein the contaminant comprises trichlorofluoromethane (R11). feeding a feed mixture comprising a hydrochlorofluoroolefin comprising a contaminant to a first distillation column; and extracting the contaminant from the feed mixture in the first distillation column using an extractive solvent comprising a chlorinated compound selected from the group consisting of trichloroethylene, carbon tetrachloride, chloroform, 1,1,1-trichloroethane, and mixtures thereof to form an overhead stream comprising a purified hydrochlorofluoroolefin and a bottoms stream comprising the contaminant and the extractive solvent; wherein the contaminant comprises trichlorofluoromethane (R11).
A vinyl acetate-ethylene copolymer emulsion prepared by using a redox initiator, wherein the redox initiator comprises a salt of at least one metal selected from the group consisting of silver (Ag), platinum (Pt), copper (Cu), mercury (Hg), zinc (Zn), tin (Sn), lead (Pb), bismuth (Bi), cadmium (Cd), and chromium (Cr), and wherein the vinyl acetate-ethylene copolymer emulsion further comprises an oligomer of a monocarboxylic acid selected from the group consisting of C 1 -C 14 aliphatic monocarboxylic acid and C 6 -C 14 aromatic monocarboxylic acid. wherein the redox initiator comprises a salt of at least one metal selected from the group consisting of silver (Ag), platinum (Pt), copper (Cu), mercury (Hg), zinc (Zn), tin (Sn), lead (Pb), bismuth (Bi), cadmium (Cd), and chromium (Cr), and wherein the vinyl acetate-ethylene copolymer emulsion further comprises an oligomer of a monocarboxylic acid selected from the group consisting of C 1 -C 14 aliphatic monocarboxylic acid and C 6 -C 14 aromatic monocarboxylic acid.
A method of operating a thermal energy exchanger for exchanging thermal energy between a thermal transfer fluid, flowing through the thermal energy exchanger in a fluid conduit , and air, being conducted through the thermal energy exchanger in an air duct , the method comprising: recording in a control system a plurality of measurement data sets, each of the measurement data sets including for a different point in time data values defining a normalized energy transfer which represents the thermal energy transferred in the thermal energy exchanger , from the thermal transfer fluid to the air, normalized by one or more normalization variables including at least one air side variable; characterised by further comprising: the control system calculating for each of the measurement data sets a normalized data point (Pn, Sn, Ln) defined by the normalized energy transfer; and the control system determining for the thermal energy exchanger a characteristic energy transfer curve (cP, cS, cL) which fits the normalized data points (Pn, Sn, Ln); and the control system controlling operating parameters, wherein the operating parameters include the flow of thermal transfer fluid through the thermal energy exchanger, the flow of air through the thermal energy exchanger, and/or the temperature of the thermal transfer fluid entering the thermal energy exchanger. recording in a control system a plurality of measurement data sets, each of the measurement data sets including for a different point in time data values defining a normalized energy transfer which represents the thermal energy transferred in the thermal energy exchanger , from the thermal transfer fluid to the air, normalized by one or more normalization variables including at least one air side variable; characterised by further comprising: the control system calculating for each of the measurement data sets a normalized data point (Pn, Sn, Ln) defined by the normalized energy transfer; and the control system determining for the thermal energy exchanger a characteristic energy transfer curve (cP, cS, cL) which fits the normalized data points (Pn, Sn, Ln); and the control system controlling operating parameters, wherein the operating parameters include the flow of thermal transfer fluid through the thermal energy exchanger, the flow of air through the thermal energy exchanger, and/or the temperature of the thermal transfer fluid entering the thermal energy exchanger.
Nicotinamide mononucleotide (NMN), a pharmaceutically acceptable derivative thereof or a pharmaceutically acceptable salt thereof, the derivative of NMN being selected from among dihydronicotinamide mononucleotide (denoted NMN-H), a compound of formula (I) or (II), a stereoisomer thereof, a salt thereof, a hydrate thereof, a solvate thereof or a crystal thereof, said compound of formula (I) being selected from among: Compounds (anomers) Structure I-C (beta) I-D (alpha) I-G (beta) I-H (alpha) I-J (beta) I-K (alpha) or: said compound of formula (II) being selected from among: Compound N° (anomer) Structure II-A (beta, beta) II-B (beta, alpha) II-C (alpha, alpha) II-D (beta, beta) II-E (beta, alpha) II-F (alpha, alpha) and combinations thereof, for use thereof in the prevention and/or treatment of pain, wherein the pain is a visceral nociceptive pain and is not a neuropathic pain. said compound of formula (II) being selected from among: Compound N° (anomer) Structure II-A (beta, beta) II-B (beta, alpha) II-C (alpha, alpha) II-D (beta, beta) II-E (beta, alpha) II-F (alpha, alpha) and combinations thereof, for use thereof in the prevention and/or treatment of pain, wherein the pain is a visceral nociceptive pain and is not a neuropathic pain.
A seat (S) provided with an armrest (T) which is pivotally displaced around one end side between a stored position where it is retracted in a posture along a seat back and a deployed position where it is deployed to a position where a free end side projects forwardly from the seat back, wherein: on the one end side of the armrest (T), a first shaft serving a pivot center is disposed so as to pass through in a width direction of the seat (S), and a second shaft passes through the one end side substantially parallel to the first shaft ; the first shaft is pivotably supported by a first hole formed in a guide member (G) fixed to a seat back frame which is a framework of the seat back, and the second shaft is inserted into a long hole-shaped second hole formed along a partial circular arc locus around the first hole so as to be movable along the second hole ; and between a side surface side of the armrest (T) and the guide member (G), a plate member which covers at least a part of the second hole is provided, the seat (S) is characterized in that the first shaft and the second shaft pass through the plate member and are fixed, wherein a third hole and a fourth hole are formed in the plate member , one of the first shaft and the second shaft is press-fitted and fixed to the third hole , and the other of the first shaft and the second shaft passes through the fourth hole perforated so as to have a larger diameter than a shaft outer diameter of the other. on the one end side of the armrest (T), a first shaft serving a pivot center is disposed so as to pass through in a width direction of the seat (S), and a second shaft passes through the one end side substantially parallel to the first shaft ; the first shaft is pivotably supported by a first hole formed in a guide member (G) fixed to a seat back frame which is a framework of the seat back, and the second shaft is inserted into a long hole-shaped second hole formed along a partial circular arc locus around the first hole so as to be movable along the second hole ; and between a side surface side of the armrest (T) and the guide member (G), a plate member which covers at least a part of the second hole is provided,
An apparatus comprising a container adapted to store a non-gaseous flowable specimen having fluidity said apparatus further comprising a gas chromatograph, the apparatus characterized in that it comprises a first flow channel connected to the gas release channel of the gas chromatograph and which is adapted to send at least a volatile component separated by the gas chromatograph into a mouth of a person, and a second flow channel adapted to send the flowable specimen into the mouth of the person.
A motor controller coupled to an electric motor and configured to: apply a first amount of current to windings of the electric motor ; determine whether the electric motor is operating in a reverse rotation direction opposite a desired direction of rotation; apply a brake to the electric motor when the electric motor is operating in the reverse rotation direction; and apply the first amount of current to the windings; characterized by further being configured to wait at least one of a predetermined time period and a predetermined number of forward rotation attempts after applying the first amount of current to the windings ; and apply a second amount of current to the windings , wherein the second amount of current is larger than the first amount. apply a first amount of current to windings of the electric motor ; determine whether the electric motor is operating in a reverse rotation direction opposite a desired direction of rotation; apply a brake to the electric motor when the electric motor is operating in the reverse rotation direction; and apply the first amount of current to the windings; characterized by further being configured to wait at least one of a predetermined time period and a predetermined number of forward rotation attempts after applying the first amount of current to the windings ; and apply a second amount of current to the windings , wherein the second amount of current is larger than the first amount.